Advertisement

Topics

Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire

16:01 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Acceleron Pharma Inc. (NASDAQ:XLRN) today announced the appointment of the experienced biopharmaceutical executive, Karen Smith, M.D., Ph.D., to its board of directors and the departure of Terrance McGuire, effective November 1...

Other Sources for this Article

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125

NEXT ARTICLE

More From BioPortfolio on "Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...